1. The p < 0.001 applied to antibody response. When it came to progression-free survival and overall survival the p-value was above 0.005 in both (0.266! in one case).
2. Merck pulled its supply agreement for the combination pembrolizumab trial
3. IMU has de-prioritised HER-Vaxx
But just because this basically means that IMU has lost a decade and tens-of-millions of dollars on a drug that has been shelved, its more important to accurately classify the phase of trials that IMU has failed to successfully complete?
Maybe you're right and it's nothing to do with IMU or its management team. Its those bloody doctors who stubbornly only prescribe FDA or TGA approved drugs instead of "validated proofs of concept".
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)